Tag:
Vion Pharmaceuticals
Latest Headlines
Latest Headlines
FDA rejects Vion's SPA for cancer drug
Vion Pharmaceuticals' hopes for a special protocol assessment intended to win an approval for its anti-cancer drug Onrigin have been dashed by the FDA. Regulators rejected the SPA request from Vion,
Cash-strapped Vion files for bankruptcy
Faced with an FDA demand to mount a new clinical trial for its late-stage cancer therapy, Vion Pharmaceuticals says it doesn't have the money to comply and has been forced to file for Chapter 11
Cash-strapped Vion ponders its next-or last-move
Delisted by Nasdaq, stymied by the FDA on its lead cancer product and suffering from a cash crunch, Vion Pharmaceuticals has brought in the investment banking firm Merriman Curhan Ford & Co. to
FDA removes hold on Vion's late-stage cancer trial
Vion Pharmaceuticals has received a green light from the FDA to resume studying the cancer drug Cloretazine as regulators removed a clinical hold on a Phase III trial of the therapy. The late stage
